USMLE Step 1 Pharmacology Core Principles
Pharmacokinetics: ADME and Clinical Relevance
Pharmacokinetics describes what the body does to the drug, fundamentally revolving around the four pillars of Absorption, Distribution, Metabolism, and Excretion (ADME). For Step 1, the most critical calculations involve Loading Dose and Maintenance Dose. The loading dose is determined by the target plasma concentration and the Volume of Distribution (Vd), which represents the theoretical volume required to contain the total amount of drug in the body at the same concentration as in the plasma. Drugs with high Vd, such as digoxin, typically distribute widely into tissues and require higher loading doses. Conversely, the maintenance dose depends on Clearance (Cl) and the dosing interval.
Metabolism often centers on the Cytochrome P450 system. You must distinguish between Phase I reactions (oxidation, reduction, hydrolysis), which often utilize the P450 enzymes to make a molecule more polar, and Phase II reactions (conjugation, such as glucuronidation or acetylation), which facilitate excretion. Clinical scenarios often test the "Slow Acetylator" phenotype, where patients have a genetic deficiency in N-acetyltransferase, leading to increased toxicity from drugs like isoniazid or hydralazine. Furthermore, understanding First-Order Kinetics—where a constant fraction of drug is eliminated per unit time—versus Zero-Order Kinetics—where a constant amount is eliminated (e.g., phenytoin, ethanol, and aspirin at high doses)—is essential for predicting drug accumulation and toxicity.
Pharmacodynamics: Receptors, Agonists, and Antagonists
Pharmacodynamics explores the drug’s effect on the body, specifically the interaction between ligands and receptors. The dose-response curve is a high-yield visual tool on the exam. You must differentiate between Potency, the amount of drug needed to produce a given effect (represented by the EC50), and Efficacy, the maximal effect a drug can produce (Emax). Step 1 often uses these curves to illustrate the impact of different types of antagonists. A Competitive Antagonist shifts the curve to the right, increasing the ED50 (decreasing potency) without changing the Emax, because the inhibition can be overcome by increasing the concentration of the agonist.
In contrast, a Noncompetitive Antagonist or an irreversible antagonist binds in a way that reduces the total number of available receptors, thereby decreasing the Emax. This is seen in the action of phenoxybenzamine on alpha-receptors. You should also be familiar with Partial Agonists, such as pindolol or buprenorphine; these agents act as agonists when given alone but function as antagonists in the presence of a full agonist because they occupy receptors without inducing a maximal response. Understanding the Therapeutic Index (LD50/ED50) is also vital, as drugs with a narrow index, like warfarin or lithium, require more intensive clinical monitoring and are frequently the subject of toxicity-related questions.
Toxicity, Drug Interactions, and Individual Variation
Exam questions regarding toxicity often present as a secondary complication in a patient being treated for a primary illness. You must recognize the classic "toxidromes" and their specific antidotes. For example, Acetaminophen toxicity is mediated by the depletion of glutathione and the accumulation of the reactive metabolite NAPQI; the treatment is N-acetylcysteine, which regenerates glutathione. Similarly, for salicylate overdose, the exam may ask for the physiological rationale behind urinary alkalinization (trapping the ionized form of the drug in the renal tubule to enhance excretion).
Drug interactions frequently involve the induction or inhibition of the CYP450 system. Potent inhibitors like grape juice, erythromycin, or cimetidine can lead to toxic levels of co-administered drugs like warfarin or theophylline. Conversely, inducers like rifampin or carbamazepine can lead to subtherapeutic levels of other medications, potentially causing treatment failure (e.g., unintended pregnancy in a patient on oral contraceptives). Individual variation often stems from Pharmacogenetics, such as G6PD deficiency, where oxidative stress from drugs like sulfonamides or primaquine leads to hemolytic anemia. Recognizing these patterns allows you to predict adverse outcomes before they are explicitly stated in a clinical vignette.
Autonomic and Cardiovascular Drug Classes
Cholinergic and Adrenergic Agents
Autonomic pharmacology Step 1 questions are foundational, requiring a mapping of receptors to their G-protein coupled signaling pathways: q, i, and s (Gq, Gi, Gs). Muscarinic receptors M1 and M3 utilize Gq (activating phospholipase C), while M2 uses Gi (inhibiting adenylyl cyclase). In the adrenergic system, Alpha-1 is Gq, Alpha-2 is Gi, and all Beta receptors (B1, B2, B3) are Gs. You must be able to predict the physiological effect of stimulating or blocking these receptors. For instance, B2 stimulation leads to bronchodilation and vasodilation via increased cAMP, while B1 stimulation increases heart rate and contractility at the SA node and myocardium.
Questions often involve the "Baroreceptor Reflex." If a drug like phenylephrine (an Alpha-1 agonist) is administered, it causes systemic vasoconstriction and an increase in Mean Arterial Pressure (MAP). The body compensates via the baroreceptor reflex, leading to an increase in vagal tone and a Reflex Bradycardia. Conversely, a vasodilator like hydralazine will trigger reflex tachycardia. You should also master the "Ephedrine Reversal" phenomenon, where the administration of an alpha-blocker before epinephrine results in a net decrease in blood pressure because the beta-2 mediated vasodilation is no longer opposed by alpha-1 mediated vasoconstriction. This level of mechanistic reasoning is what the USMLE uses to distinguish high-performing candidates.
Antihypertensives and Antiarrhythmics
Cardiovascular pharmacology requires an integrated understanding of the Renin-Angiotensin-Aldosterone System (RAAS) and cardiac electrophysiology. ACE Inhibitors like lisinopril prevent the conversion of Angiotensin I to Angiotensin II, but they also inhibit the breakdown of bradykinin, leading to the classic side effect of a dry cough. If a patient develops angioedema or a persistent cough, the exam will often suggest switching to an Angiotensin II Receptor Blocker (ARB) like losartan, which does not affect bradykinin levels. You must also understand the role of Calcium Channel Blockers (CCBs), distinguishing between the dihydropyridines (e.g., amlodipine) which act primarily on peripheral vasculature, and non-dihydropyridines (e.g., verapamil, diltiazem) which have significant negative inotropic and chronotropic effects on the heart.
In the realm of cardiovascular pharmacology review, antiarrhythmics are categorized by the Vaughan Williams classification. Class I agents are sodium channel blockers, with Class IC (e.g., flecainide) showing the strongest use-dependence, meaning their effect increases at higher heart rates. Class III agents, such as amiodarone or sotalol, are potassium channel blockers that prolong the QT interval by extending the action potential duration. Amiodarone is particularly high-yield due to its unique side-effect profile, including pulmonary fibrosis, thyroid dysfunction (due to its high iodine content), and corneal deposits. Understanding the phase of the cardiac action potential targeted by each class—such as Class IV CCBs affecting the Phase 0 depolarization of the SA/AV nodes—is essential for answering mechanism-of-action questions.
Diuretics and Heart Failure Medications
Diuretics are tested by their specific site of action within the nephron. Loop diuretics (e.g., furosemide) inhibit the Na+/K+/2Cl- cotransporter in the thick ascending limb, which also disrupts the corticomedullary gradient and leads to significant calcium excretion ("Loops lose calcium"). In contrast, Thiazide diuretics act on the distal convoluted tubule and are actually calcium-sparing, making them a preferred choice for hypertensive patients with osteoporosis. Potassium-sparing diuretics like spironolactone or eplerenone are aldosterone antagonists used in heart failure to prevent cardiac remodeling and reduce mortality, but they carry a risk of hyperkalemia.
Management of chronic heart failure focuses on drugs that provide a survival benefit, specifically ACE inhibitors, ARBs, certain Beta-blockers (carvedilol, metoprolol succinate, bisoprolol), and aldosterone antagonists. During acute decompensated heart failure, the focus shifts to reducing preload and afterload using diuretics and vasodilators. You may also encounter Sacubitril, a neprilysin inhibitor that increases levels of natriuretic peptides; it is always used in combination with an ARB (Valsartan) to prevent the accumulation of bradykinin. Understanding the shift from symptomatic relief (digoxin, which inhibits the Na+/K+ ATPase) to mortality-reducing therapies is a frequent theme in clinical management questions.
Central Nervous System Pharmacology
Anesthetics, Analgesics, and Local Anesthetics
CNS drugs Step 1 coverage includes the principles of general anesthesia, specifically the concepts of Minimum Alveolar Concentration (MAC) and solubility. MAC is a measure of potency; the lower the MAC, the more potent the anesthetic. Solubility is determined by the blood/gas partition coefficient; agents with low solubility (like nitrous oxide) reach equilibrium quickly, leading to rapid induction and recovery. Conversely, highly soluble agents (like halothane) have a slower onset. You should also be aware of the risk of Malignant Hyperthermia associated with inhaled anesthetics and succinylcholine, triggered by a defect in the ryanodine receptor leading to massive calcium release from the sarcoplasmic reticulum, treated with Dantrolene.
Analgesics are dominated by opioids and NSAIDs. Opioids act as agonists at mu-receptors, which are G-protein coupled receptors that close presynaptic calcium channels and open postsynaptic potassium channels, leading to hyperpolarization and reduced neurotransmitter release. Common side effects like constipation and miosis do not show tolerance, unlike respiratory depression or euphoria. Local anesthetics (esters like procaine and amides like lidocaine) work by binding to and blocking activated sodium channels from the inside of the cell membrane. They preferentially bind to rapidly firing nerves (use-dependent blockade) and are often co-administered with epinephrine to cause local vasoconstriction, which decreases systemic absorption and prolongs the duration of action.
Psychopharmacology: Antidepressants and Antipsychotics
Psychiatric medications are often tested via their receptor profiles and side effects. Selective Serotonin Reuptake Inhibitors (SSRIs) are first-line for depression, but you must recognize the risk of Serotonin Syndrome if they are combined with other serotonergic agents like MAO inhibitors or linezolid. This syndrome presents with hyperreflexia, clonus, and autonomic instability. Antipsychotics are divided into first-generation (D2 antagonists) and second-generation (5-HT2 and D2 antagonists). First-generation agents like haloperidol are high-potency and frequently cause Extrapyramidal Symptoms (EPS) such as acute dystonia, akathisia, and tardive dyskinesia due to the blockade of the nigrostriatal pathway.
Second-generation antipsychotics, such as clozapine and olanzapine, are more associated with metabolic side effects, including weight gain and hyperglycemia. Clozapine is specifically noted for the risk of agranulocytosis, requiring regular monitoring of the absolute neutrophil count (ANC). Lithium, used for bipolar disorder, has a narrow therapeutic window and can cause nephrogenic diabetes insipidus or Ebstein’s anomaly in the fetuses of pregnant patients. Understanding the mechanism of Tricyclic Antidepressants (TCAs) is also crucial; they inhibit the reuptake of norepinephrine and serotonin but also block alpha-1, histamine H1, and muscarinic receptors, leading to their extensive side-effect profile (the "3 Cs": Coma, Convulsions, Cardiotoxicity).
Antiepileptics and Drugs for Neurodegenerative Diseases
Antiepileptic drugs (AEDs) utilize various mechanisms to reduce neuronal excitability. Phenytoin and carbamazepine stabilize the inactivated state of sodium channels. Valproic acid has a broad mechanism, increasing GABA concentrations and blocking sodium channels, but it is highly teratogenic (neural tube defects). Ethosuximide is the specific treatment for absence seizures, acting by blocking T-type calcium channels in the thalamus. For status epilepticus, the immediate treatment is a benzodiazepine (enhancing GABA-A channel opening frequency), followed by phenytoin for long-term seizure control.
Neurodegenerative disease pharmacology focuses on Parkinson’s and Alzheimer’s. In Parkinson’s, the goal is to increase dopamine levels in the striatum. Levodopa is a precursor that can cross the blood-brain barrier, administered with Carbidopa (a peripheral DOPA decarboxylase inhibitor) to reduce peripheral side effects like nausea and cardiac arrhythmias. You should also know the role of MAO-B inhibitors (selegiline) and COMT inhibitors (entacapone) in preventing dopamine breakdown. For Alzheimer’s, the focus is on increasing acetylcholine using acetylcholinesterase inhibitors like donepezil, or blocking NMDA-mediated excitotoxicity with memantine. These drugs do not cure the disease but provide symptomatic improvement in cognitive function.
Antimicrobial and Chemotherapeutic Agents
Antibiotics: Mechanisms, Spectrum, and Resistance
Antimicrobials USMLE questions require a precise understanding of the bacterial cell wall and protein synthesis machinery. Cell wall synthesis inhibitors include the beta-lactams (penicillins, cephalosporins, carbapenems) and vancomycin. Beta-lactams inhibit Penicillin-Binding Proteins (PBPs), which are responsible for cross-linking the peptidoglycan layer. Resistance often occurs via beta-lactamase production, prompting the use of inhibitors like clavulanic acid. Vancomycin, however, binds to the D-Ala-D-Ala terminus of nascent peptidoglycan pentapeptide, inhibiting transglycosylation. Resistance to vancomycin occurs through the modification of this target to D-Ala-D-Lac.
Protein synthesis inhibitors target either the 30S or 50S ribosomal subunits. Aminoglycosides (e.g., gentamicin) and Tetracyclines target the 30S subunit, while Macrolides (e.g., azithromycin), Chloramphenicol, and Linezolid target the 50S subunit. Aminoglycosides are unique among these as they are bactericidal and require oxygen for uptake, making them ineffective against anaerobes. They are also notoriously nephrotoxic and ototoxic. Fluoroquinolones (e.g., ciprofloxacin) inhibit DNA gyrase (Topoisomerase II) and Topoisomerase IV, preventing DNA replication. You must also know the mechanism of sulfonamides and trimethoprim, which sequentially inhibit the synthesis of tetrahydrofolate, a necessary cofactor for nucleic acid synthesis.
Antifungal, Antiviral, and Antiparasitic Drugs
Antifungal medications target the fungal cell membrane or wall. Amphotericin B and nystatin bind to ergosterol, creating pores in the membrane, while the -azoles (e.g., fluconazole) inhibit the synthesis of ergosterol by blocking the enzyme 14-alpha-demethylase. Echinocandins (e.g., caspofungin) inhibit the synthesis of beta-glucan, a key component of the fungal cell wall. Antiviral therapy for HIV, known as HAART, involves combinations of drugs like Nucleoside Reverse Transcriptase Inhibitors (NRTIs), which act as chain terminators, and Protease Inhibitors, which prevent the cleavage of the gag-pol polyprotein into functional units.
For Herpes Simplex Virus (HSV) and Varicella-Zoster Virus (VZV), Acyclovir is the prototype drug. It is a guanosine analog that must be monophosphorylated by viral Thymidine Kinase before it can be further activated by host cell kinases; this step provides specificity, as the drug is only activated in infected cells. For Hepatitis C, modern treatments include direct-acting antivirals like sofosbuvir (an RNA polymerase inhibitor). Antiparasitic drugs such as chloroquine (for malaria) work by preventing the detoxification of heme in Plasmodium species. Resistance to chloroquine is widespread due to membrane pumps that efflux the drug, requiring the use of artemisinins or mefloquine.
Cancer Chemotherapy and Immunosuppressants
Chemotherapeutic agents are classified by their action on the cell cycle. Antimetabolites like Methotrexate (a dihydrofolate reductase inhibitor) and 5-Fluorouracil (a thymidylate synthase inhibitor) act during the S-phase. Alkylating agents like cyclophosphamide cross-link DNA and are cell-cycle non-specific, but carry the risk of hemorrhagic cystitis, which can be mitigated with Mesna. Microtubule inhibitors like vincristine and vinblastine inhibit polymerization (M-phase arrest), while taxanes like paclitaxel inhibit depolymerization. A classic side effect of vincristine is peripheral neuropathy.
Immunosuppressants are critical for transplant medicine and autoimmune disease. Cyclosporine and tacrolimus are calcineurin inhibitors that prevent the transcription of IL-2, thereby inhibiting T-cell activation. Their primary toxicity is nephrotoxicity. Sirolimus (mTOR inhibitor) also prevents IL-2 signaling but acts further downstream and is notably not nephrotoxic, though it causes cytopenias. Mycophenolate mofetil inhibits IMP dehydrogenase, disrupting de novo purine synthesis in B and T cells. Biological agents like Infliximab (anti-TNF-alpha) are used in Crohn’s disease and rheumatoid arthritis but require screening for latent tuberculosis prior to initiation, as TNF is essential for granuloma maintenance.
Endocrine, Renal, and Gastrointestinal Pharmacology
Insulin, Oral Hypoglycemics, and Steroid Hormones
Diabetes management involves a variety of mechanisms to lower blood glucose. Insulin itself is categorized by its onset and duration, from rapid-acting (Lispro, Aspart) to long-acting (Glargine, Detemir). Among oral agents, Metformin is first-line; it inhibits hepatic gluconeogenesis and increases peripheral insulin sensitivity via AMPK activation. It does not cause hypoglycemia but carries a risk of lactic acidosis, especially in patients with renal impairment. Sulfonylureas (e.g., glipizide) stimulate insulin release by closing ATP-sensitive potassium channels in pancreatic beta cells, which leads to depolarization and calcium influx.
Other agents include SGLT2 inhibitors (e.g., canagliflozin), which block glucose reabsorption in the proximal tubule, leading to glucosuria and potential urinary tract infections. Glucagon-like peptide-1 (GLP-1) agonists like exenatide increase glucose-dependent insulin secretion and delay gastric emptying. In the realm of steroid hormones, questions often focus on the hypothalamic-pituitary-adrenal axis. Chronic glucocorticoid use leads to adrenal atrophy due to negative feedback on ACTH. When discontinuing long-term steroids, the dose must be tapered to allow the adrenal glands to recover function and prevent acute adrenal insufficiency.
Drugs Affecting Renal and Electrolyte Balance
Beyond diuretics, renal pharmacology involves the management of chronic kidney disease (CKD) complications. Erythropoiesis-stimulating agents (ESAs) like epoetin alfa are used to treat the anemia of CKD, but they increase the risk of hypertension and thromboembolic events. Phosphate binders like sevelamer are used to manage hyperphosphatemia. In patients with hyperkalemia, potassium binders like sodium polystyrene sulfonate or patiromer may be used, though acute management involves stabilizing the cardiac membrane with calcium gluconate and shifting potassium intracellularly with insulin and glucose.
Vasopressin (ADH) antagonists, known as Vaptans (e.g., conivaptan, tolvaptan), are used in the treatment of SIADH (Syndrome of Inappropriate Antidiuretic Hormone) by blocking V2 receptors in the collecting duct, thereby increasing free water excretion. Conversely, Desmopressin is a V2 agonist used to treat central diabetes insipidus. You must distinguish between central DI (lack of ADH) and nephrogenic DI (resistance to ADH). If a patient with nephrogenic DI is treated with desmopressin, there will be no change in urine osmolality, whereas a patient with central DI will show a significant increase.
Gastric acid suppression is achieved through Proton Pump Inhibitors (PPIs) like omeprazole, which irreversibly inhibit the H+/K+ ATPase in parietal cells. They are more effective than H2-receptor antagonists like ranitidine. Long-term PPI use is associated with decreased absorption of magnesium and calcium, as well as an increased risk of C. difficile infection. For treating peptic ulcer disease caused by H. pylori, a triple therapy consisting of a PPI, clarithromycin, and amoxicillin (or metronidazole) is standard.
Motility disorders are managed with prokinetic agents like Metoclopramide, a D2 receptor antagonist that increases resting tone and contractility in the upper GI tract. However, its dopamine-blocking effects can lead to parkinsonian side effects or tardive dyskinesia. For inflammatory bowel disease, 5-aminosalicylates like sulfasalazine are used for maintenance, while acute flares may require corticosteroids. Antiemetics like Ondansetron (a 5-HT3 antagonist) are highly effective for chemotherapy-induced nausea, acting both peripherally on vagal nerve terminals and centrally in the area postrema.
Applying Pharmacology to Step 1 Practice Questions
Identifying Drug-Disease Pairings in Vignettes
Step 1 questions often provide a detailed clinical history and then ask for the most appropriate management. Success depends on recognizing the "buzzword" clinical features of a disease and pairing them with the gold-standard treatment. For example, a patient with a history of smoking, weight loss, and a central lung mass likely has small cell lung cancer; if the question asks about an associated paraneoplastic syndrome like SIADH, you must then identify the correct pharmacological intervention, such as fluid restriction or a V2 antagonist. This requires a three-step mental process: diagnosis, pathophysiology, and then pharmacology.
Predicting Side Effects from Drug Profiles
Many questions focus on the "next best step" or "most likely adverse effect." If a patient is started on an ACE inhibitor and develops a dry cough, the mechanism involves the accumulation of bradykinin. If a patient on a statin develops muscle pain and dark urine, you must recognize Rhabdomyolysis and check creatine kinase levels. The exam often tests side effects that are unique or life-threatening. For instance, knowing that Ethambutol causes optic neuritis (red-green color blindness) or that Pyrazinamide causes hyperuricemia (potentially triggering gout) is essential for answering questions about tuberculosis treatment regimens.
Using Mechanism to Eliminate Incorrect Answer Choices
When faced with an unfamiliar drug name, focus on the suffix or the class-wide mechanism. If you know a drug ends in "-stigmine," it is an acetylcholinesterase inhibitor. If a question asks which drug would be contraindicated in a patient with a specific condition, use your knowledge of the drug’s mechanism to rule out options. For example, if a patient has asthma, you should avoid non-selective beta-blockers like propranolol because B2 blockade causes bronchoconstriction. By systematically applying the physiological logic of drug-receptor interactions, you can narrow down the choices even when the specific clinical scenario is complex or novel. This analytical approach is the hallmark of a successful USMLE Step 1 pharmacology review strategy.